stockrow
Friday 6 November 2026
Export VKTX’s income statement to Excel — free account
Viking Therapeutics, Inc.
VKTX Healthcare Biotechnology
- EPS
- −91.6%
- Free cash flow
- −47.0%
Quarter to September 2026, against a year earlier
26.82
1.03
+3.99%
Follow VKTX
Alert me
Viking Therapeutics, Inc. (VKTX) Book value per share
Viking Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 5.7×, down 29.7% from 8.1× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 5.0×. Over the past ten years it has ranged from 0.5× (fiscal 2016) to 8.1× (fiscal 2024); the current reading is higher than 91% of that period. Viking Therapeutics, Inc. ranks 156th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 5.7× | (29.74%) |
| FY2024 | 8.1× | 118.61% |
| FY2023 | 3.7× | 95.25% |
| FY2022 | 1.9× | (27.67%) |
| FY2021 | 2.6× | (22.30%) |
| FY2020 | 3.4× | (12.60%) |
| FY2019 | 3.9× | (25.53%) |
| FY2018 | 5.2× | 897.70% |
| FY2017 | 0.5× | 4.90% |
| FY2016 | 0.5× | (64.01%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 5.0× | 41.97% |
| Jun 2026 | 3.5× | (19.13%) |
| Mar 2026 | 4.3× | (23.43%) |
| Dec 2025 | 5.7× | (10.65%) |
| 43 more quarters | Free account |
Against its own ten years
Low 0.5×
High 8.1×
Ten-year median
3.4×
Current reading's percentile
91
Book value per share against peers
| Company | Book value per share |
|---|---|
| PBLS Parabilis Medicines, Inc. compare | 36.2× |
| IRON Disc Medicine, Inc. compare | 16.7× |
| ELVN Enliven Therapeutics, Inc. compare | 13.5× |
| XENE Xenon Pharmaceuticals Inc. compare | 12.5× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 8.0× |
| VKTX Viking Therapeutics, Inc. | 5.0× |
| DYN Dyne Therapeutics, Inc. compare | 4.2× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 2.2× |
| CELC Celcuity, Inc. compare | −0.2× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))